eStudy Site on Muck Rack

eStudy Site

As seen in: SKIN The Journal of Cutaneous Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with eStudy

Contact eStudy, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase I Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects with Actinic Keratosis

|
By J. Scott Overcash, eStudy Site, La Mesa, Regina Yavel
| SKIN The Journal of Cutaneous Medicine Verified
Main Article Content Regina Yavel TKL Research Inc., Fair Lawn, NJ, USA J. Scott Overcash eStudySite, La Mesa, CA, USA Jay Zhi Athenex Inc., Buffalo, NY Eva Cutler Athenex Inc., Buffalo, NY David Cutler Athenex Inc., Buffalo, NY Jane Fang Athenex Inc., Buffalo, NY, USA Keywords Skin Cancer, Actinic Keratosis, Src Kinase Inhibitor, Tirbanibulin Abstract Abstract not available. References 1. Smolinksi MP, et al J Med Chem 2018 61 4707 4719 2.
Open in Who Shared Issue with article?

Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis)

|
By J. Scott Overcash, La Mesa, Courtney A. Tiffany, eStudy Site
| American Society for Microbiology (ASM)
Clinical Therapeutics J. Scott Overcash, Courtney A. Tiffany, Nicole E. Scangarella-Oman, Caroline R. Perry, Yu Tao, Mohammad Hossain, Aline Barth, Etienne F. Dumont DOI: 10.1128/AAC.00199-20 ABSTRACT Gepotidacin, a triazaacenaphthylene bacterial type II topoisomerase inhibitor, is in development for treatment of uncomplicated urinary tract infection (uUTI).
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified